RESOURCE / PUBLIC SOURCE RECORD
Join Team Norway at Nordic Health Summit Japan 2025
- Event listing gives 24–27 June 2025 at Takeda Global Headquarters, Tokyo; category: exhibition; industry: health and life science. Organisers: Innovation Norway and the Royal Norwegian Embassy in Tokyo. Contact: Marianne Støren Berg (marianne.storen.berg@innovationnorway.no). The page describes this as the summit’s fourth edition, attended by Japanese pharmaceutical companies and investors.
- The summit is positioned as a partnering and investor conference for Nordic healthcare innovators and Japanese investors/industry, with curated matchmaking. Norwegian start-ups and scale-ups were invited to explore Japanese life-science and healthcare collaborations. Participation could be online or in Tokyo; registration was linked to nordichealthsummit.org.
- Listed programme: 24 June Market Entry Day in Tokyo, including visits to a Japanese hospital and nursing home to examine care in an ageing society, universal healthcare and applied AI; 27 June summit at Takeda’s Tokyo headquarters. Benefits named include market insight, access to Japanese life-science investors and industrial partners, curated collaboration/investment matchmaking and industry networking. The page also linked to a separate Norwegian radiopharma/precision-oncology trade mission.
- Japan-market context stated on the page: population 125 million; described as the world’s third-largest healthcare market; 2018–2024 market growth projection of 4% CAGR; named major firms Takeda, Astellas and Eisai. It says a relatively small domestic start-up scene leads Japanese firms to seek international innovation partners, citing Eisai’s Swedish partnership connected to the first FDA-approved Alzheimer’s drug in 2023 and Fujifilm’s stated $1.6 billion Danish advanced-manufacturing investment. It also notes universal coverage, freedom to choose providers, and healthcare spending said to have risen over 30% since 2000 to 11% of GDP. No participation fee, detailed summit agenda or exhibitor roster shown. ESG and responsible-business due-diligence conditions applied.